Compare GSK plc (GSK) vs Schlumberger NV (SLB) Price & Performance

GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.

The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.

SLB (NYSE: SLB) trades at $53.02, down 0.34% on the day, with strong technical momentum as moving averages signal bullish sentiment. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $0.55 exceeding expectations. Revenue trends show stability at $35.7B in 2025, though net income margin declined to 8.53%. Analyst consensus remains overwhelmingly positive with 85% buy ratings and a $63 price target representing 19% upside potential.

SLB's outlook is supported by robust digital and production systems growth, though Middle East exposure and net debt pose near-term risks. The stock offers 2.25% dividend yield with recent quarterly payouts of $0.30. While technical indicators show some overbought conditions with RSI at 74, fundamental strength and Wall Street optimism suggest continued upside potential, balanced by geopolitical and margin compression risks.